Clinical Trial

Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Name: Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia — clinical trial record (NCT07637929)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

Establishing real-world data of Chinese patients with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) treated with Puzolcabtagene Autoleucel Injection to evaluate its effectiveness.

Trial Details

NCT Number	NCT07637929
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Enrollment	200 participants
Start Date	2026-06
Primary Completion	2032-12 (estimated)
Study Completion	2032-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-10